Eli Lilly reports positive data from Phase III HFpEF treatment trial

Lilly's tirzepatide successful in phase 3 study showing benefit in ...

1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial ...

Eli Lilly and Company has announced positive topline data from the Phase III trial of tirzepatide in adults with HFpEF and obesity.

Eli Lilly reports positive data from Phase III HFpEF treatment trial

Tirzepatide led to a 15.7% body weight reduction compared to 2.2% for placebo for the efficacy estimand, and a 13.9% reduction against 2.2% for ...

Eli Lilly eyes tirzepatide cardio filings after late-stage win

In the phase 3 SUMMIT trial, Lilly's tirzepatide reduced the risk of adverse HF outcomes—such as hospitalization or cardiovascular death—by 38% ...

Lilly's tirzepatide successful in phase 3 study showing benefit in ...

1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial ...

Eli Lilly's Tirzepatide Shows Reduction in Risk of Heart Failure ...

Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.

Tirzepatide successful in phase III study showing benefit in adults ...

Eli Lilly and Company announced positive topline results from the SUMMIT phase III clinical trial evaluating the safety and efficacy of ...

Tirzepatide Meets Both Primary End Points in Phase 3 SUMMIT Trial

Trial Name: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The ...

Lilly obesity drug shows heart benefit in late-stage trial

The drug led to a 38% reduction in the risk of death or complications from a common type of heart failure, data that Lilly intends to share with ...

Tirzepatide Reduces Heart Failure Outcomes in Obesity-Related ...

... HFpEF and obesity in the phase 3 SUMMIT trial ... Eli Lilly and Company have announced positive topline data from ...

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in ...

For the treatment-regimen estimandiii, pooled doses of tirzepatide resulted in a significant 93% reduction in risk of progression to type 2 ...

Eli Lilly declares positive data from Phase III HFpEF treatment trial

Eli Lilly has announced positive results from the Phase III SUMMIT trial of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) ...

Q2 2024 Lilly Presentation

Phase 3 Data Disclosures. Tirzepatide for ... • Announced positive topline results from the SUMMIT Phase 3 trial of tirzepatide in heart.

Lilly's Tirzepatide Clears Phase III Cardiovascular Study on Heels of ...

Eli Lilly on Thursday released late-stage data showing a 38% reduction in the risk of heart failure outcomes, as it plays catch-up with Novo ...

Lilly Reports Positive Topline Results From SUMMIT Phase 3 Study ...

Eli Lilly and Company (LLY) Thursday announced positive topline results from the SUMMIT phase 3 study evaluating tirzepatide in adults with heart failure ...

q3 2024 earnings call - Eli Lilly Investors

• Presented positive data from our Phase 3 TRAILBLAZER-ALZ 6 trial evaluating ... Phase 3 Data Disclosures. Tirzepatide for obstructive ...

Eli Lilly's tirzepatide shows positive results in heart-failure-treatment ...

The Phase 3 trial evaluated 5mg, 10mg and 15mg doses of tirzepatide and demonstrated statistically significant improvements in primary and ...

Eli Lilly touts tirzepatide's midstage MASH win - Fierce Pharma

Tirzepatide's latest phase 2 win adds to a positive sign reported back in 2021. In a sub-study of the phase 3 SURPASS-3 trial, tirzepatide ...

Breakthrough results for Jardiance® (empagliflozin) confirm ...

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection ...

Boehringer and Lilly report positive data from EMPEROR-Preserved ...

The trial tested the safety and efficacy of Jardiance in patients with chronic HFpEF. ... Jardiance demonstrated 21% reduction in risk of ...